BY-COVID WP5 T5.2 Baseline Use Case

Download all the metadata for BY-COVID WP5 T5.2 Baseline Use Case in JSON-LD format

Check this crate

Download this dataset: BY-COVID WP5 T5.2 Baseline Use Case

BY-COVID WP5 T5.2 Baseline Use Case

@id	./
name [?]	BY-COVID WP5 T5.2 Baseline Use Case
@type	Dataset
description [?]	This publication corresponds to the Research Objects (RO) of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection”.
funder [?]	European Commission
datePublished [?]	2023-04-19
author [?]	• Francisco Estupiñán-Romero • Nina Van Goethem • Marjan Meurisse • Javier González-Galindo • Enrique Bernal-Delgado
conformsTo [?]	Process Run Crate
codeRepository [?]	https://github.com/by-covid/BY-COVID_WP5_T5.2_baseline-use-case
hasPart [?]	• BY-COVID - WP5 - Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Analytical pipeline • BY-COVID - WP5 - Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Causal Model • COVID-19 vaccine(s) effectiveness assessment (synthetic dataset) • BY-COVID - WP5 - Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Data Management Plan • BY-COVID - WP5 - Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Study protocol • Common data model specification • README.md
distribution [?]	https://github.com/by-covid/BY-COVID_WP5_T5.2_baseline-use-case/archive/refs/heads/main.zip
identifier [?]	https://doi.org/10.5281/zenodo.6913045
cite-as [?]	https://w3id.org/ro/doi/10.5281/zenodo.6913045
isBasedOn [?]	• https://github.com/by-covid/BY-COVID_WP5_T5.2_baseline-use-case/releases/tag/1.0.1 • https://doi.org/10.5281/zenodo.6913045 • https://doi.org/10.5281/zenodo.7551181 • https://doi.org/10.5281/zenodo.7625783
keywords [?]	COVID-19, vaccines, comparative effectiveness, causal inference, international comparison, SARS-CoV-2, common data model, directed acyclic graph, synthetic data
license [?]	Creative Commons Attribution 4.0 International
dateModified [?]	2023-10-05
publisher [?]	BY-COVID
funding [?]	HORIZON-INFRA-2021-EMERGENCY-01 101046203
mentions [?]	• Generating HTML from QMD • Execution of pandas-profiling for exploratory data analysis • dataspice JSON-LD created from CSV templates • Second (?) execution of Jupyter Notebook to generate 650k synthetic dataset • Execution of Jupyter Notebook to generate 10k synthetic dataset • RO-Crate metadata created based on README and dataspice JSON-LD
url [?]	https://by-covid.github.io/BY-COVID_WP5_T5.2_baseline-use-case/
version [?]	1.2.0
assesses [?]	Research Question: How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?
material [?]	Cohort definition: All individuals (from 5 to 115 years old, included) vaccinated with at least one dose of the SARS-CoV-2 vaccine (any of the available brands) and all individuals eligible to be vaccinated with a documented positive diagnosis (irrespective of the type of test) for a SARS-CoV-2 infection during the data extraction period.
materialExtent [?]	Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any of the available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of data extraction. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included)
publishingPrinciples [?]	Study Design: An observational retrospective longitudinal study to assess the effectiveness of the SARS-CoV-2 vaccines in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries. A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome.
temporalCoverage [?]	Study Period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country.
usageInfo [?]	The scripts (software) included in the publication are offered "as-is", without warranty, and disclaiming liability for damages resulting from using it. The software is released under the CC-BY-4.0 licence, which gives you permission to use the content for almost any purpose (but does not grant you any trademark permissions), so long as you note the license and give credit.
releaseNotes [?]	- Updated Causal model to eliminate the consideration of 'vaccination_schedule_cd' as a mediator - Adjusted the study period to be consistent with the Study Protocol - Updated 'sex_cd' as a required variable - Added 'chronic_liver_disease_bl' as a comorbidity at the individual level - Updated 'socecon_lvl_cd' at the area level as a recommended variable -Added crosswalks for the definition of 'chronic_liver_disease_bl' in a separate sheet -Updated the 'vaccination_schedule_cd' reference to the 'Vaccine' node in the updated DAG -Updated the description of the 'confirmed_case_dt' and 'previous_infection_dt' variables to clarify the definition and the need for a single registry per person

Items that reference this one

about [?]	• ro-crate-metadata.json • README.md